Premium
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Cr... Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Show more
NOVATO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...
Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to...
NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...
NOVATO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...
NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study...
NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.8833 | 2.0366612866 | 43.37 | 44.5299 | 41.89 | 521074 | 43.0061115 | CS |
| 4 | 1.1433 | 2.65205288796 | 43.11 | 46.24 | 39.79 | 852355 | 42.40914611 | CS |
| 12 | -6.0267 | -11.9862768496 | 50.28 | 50.48 | 39.79 | 817559 | 44.25183213 | CS |
| 26 | -2.7067 | -5.76384156729 | 46.96 | 60.37 | 39.79 | 758139 | 49.39670332 | CS |
| 52 | 1.6333 | 3.83223838573 | 42.62 | 60.37 | 37.02 | 778571 | 46.80565038 | CS |
| 156 | -23.1167 | -34.3130473505 | 67.37 | 85.53 | 31.52 | 717688 | 46.08573072 | CS |
| 260 | -10.2567 | -18.8161805173 | 54.51 | 179.647 | 31.52 | 618612 | 60.15506553 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
